The US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory Imaging (FRI) parameters to physicians via an online... View Article
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with unclear etiology. IPF patients decline with heterogeneous trajectories. The ability to determine an individual’s disease course is limited to pulmonary function measurement... View Article
Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI... View Article